Atea Pharmaceuticals, Inc. (AVIR)
- Sector
- Pharmaceuticals
- Last price
- $4.27
- As of
Kresmion compiles this page from AVIR's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Atea Pharmaceuticals, Inc. (AVIR): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-12.
See the full AVIR dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for AVIR on one page. Preview it with sample data, then open it live with a free account.
Preview the AVIR dossierActive events for AVIR
- mediumEarnings above estimates
Q2-2026: Beat consensus by 28.2%, EPS $-0.41 vs $-0.5712 estimate
- high13F: large increase
CITADEL ADVISORS LLC added +268% to AVIR (2026Q2)
- high13F: large increase
Point72 Asset Management, L.P. added +87% to AVIR (2026Q1)
- high13F: large increase
TWO SIGMA INVESTMENTS, LP added +150% to AVIR (2026Q1)
- mediumEarnings below estimates
Q3-2025: Missed consensus by 18.1% - EPS $-0.53 vs $-0.4488 estimate
FREE, NO ACCOUNT
Every event on AVIR, as it fires
You are seeing 5 of 7 events recorded on AVIR since 2026-05-26.
The five above landed across 4 days. The other 2 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in AVIR (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 04683R106 · 2026Q2 | $7M | 0.01% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 04683R106 · 2026Q2 | $5.3M | 0.01% | , |
| D. E. Shaw & Co., Inc.CUSIP 04683R106 · 2026Q2 | $1.6M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 04683R106 · 2026Q2 | $1.4M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 04683R106 · 2026Q2 | $731K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, AVIR
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
AVIR against its peers
AVIR's return on equity of -57.5% ranks in the 24th percentile of 22 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-03-31 and 2026-06-30.
| Metric | AVIR | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 347M | n/a | 20 |
| Gross margin | n/a | 73.3% | n/a | 11 |
| Operating margin | n/a | 8.5% | n/a | 19 |
| Net margin | n/a | 0.5% | n/a | 19 |
| Return on equity | -57.5% | -6.5% | 24 | 22 |
| P / E | n/a | 14.2x | n/a | 9 |
Peers (25): FULC, BIOA, ACB, SIGA, ACRS, COLL, ESPR.D, ALMS, ANRO, AMPH, OMER, NKTR, PCRX, INVA, GPCR, PAHC, OCUL, NUVB, ANIP, TRVI, XERS, PLRX, HRMY, SUPN, BHC. Fiscal periods ending between 2025-03-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (AVIR: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow AVIR on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to AVIR for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.